Rocket Pharmaceuticals Key Executives
This section highlights Rocket Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Rocket Pharmaceuticals
(Showing 0 of )
Rocket Pharmaceuticals Earnings
This section highlights Rocket Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Rocket Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $7.10M | $6.27M | $5.37M | $1.15M |
| Gross Profit | $- | $-7.10M | $-6.27M | $-5.37M | $-1.15M |
| Gross Profit Ratio | 0.00% | - | - | - | - |
| Research and Development Expenses | $171.24M | $180.97M | $165.57M | $125.48M | $106.38M |
| General and Administrative Expenses | $101.96M | $73.32M | $58.77M | $41.77M | $27.92M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $101.96M | $73.32M | $58.77M | $41.77M | $27.92M |
| Other Expenses | $- | $- | $-500.00K | $-1.00M | $- |
| Operating Expenses | $273.20M | $259.66M | $223.84M | $166.25M | $134.30M |
| Cost and Expenses | $- | $259.66M | $223.84M | $166.25M | $134.30M |
| Interest Income | $- | $15.94M | $3.89M | $3.07M | $2.15M |
| Interest Expense | $-1.89M | $1.88M | $1.91M | $5.89M | $7.55M |
| Depreciation and Amortization | $-12.57M | $7.10M | $6.27M | $5.37M | $1.15M |
| EBITDA | $-273.20M | $-236.62M | $-213.69M | $-161.72M | $-131.59M |
| EBITDA Ratio | - | - | - | - | - |
| Operating Income | $-273.20M | $-259.66M | $-224.34M | $-167.25M | $-134.30M |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $14.46M | $14.06M | $2.48M | $-1.82M | $-5.40M |
| Income Before Tax | $-258.75M | $-245.59M | $-221.86M | $-169.07M | $-139.70M |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $- | $- | $-2.48M | $516.00K | $6.97M |
| Net Income | $-258.75M | $-245.59M | $-219.38M | $-169.59M | $-146.67M |
| Net Income Ratio | - | - | - | - | - |
| EPS | $-2.73 | $-2.92 | $-3.22 | $-2.68 | $-2.65 |
| EPS Diluted | $-2.73 | $-2.92 | $-3.22 | $-2.68 | $-2.65 |
| Weighted Average Shares Outstanding | 94.81M | 84.01M | 68.15M | 63.24M | 55.38M |
| Weighted Average Shares Outstanding Diluted | 94.81M | 84.01M | 68.15M | 63.24M | 55.38M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $10.31M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $2.34M | $2.25M | $5.16M | $1.76M | $1.72M | $1.67M | $1.78M | $1.64M | $1.57M | $1.30M | $3.19M | $800.00K | $700.00K | $674.00K | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-2.34M | $-2.25M | $5.16M | $-1.76M | $-1.72M | $-1.67M | $-1.78M | $-1.64M | $-1.57M | $-1.30M | $-3.19M | $-800.00K | $-700.00K | $-674.00K | $- | $- | $- | $- |
| Gross Profit Ratio | - | 0.00% | - | - | 50.00% | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $37.36M | $42.31M | $44.79M | $43.76M | $41.74M | $46.84M | $51.38M | $46.37M | $50.04M | $43.38M | $41.36M | $30.79M | $32.16M | $39.98M | $24.80M | $28.54M | $51.04M | $21.66M | $16.73M | $16.96M |
| General and Administrative Expenses | $25.34M | $27.11M | $27.37M | $22.15M | $21.54M | $18.59M | $17.37M | $15.82M | $19.05M | $15.11M | $12.85M | $11.77M | $12.17M | $9.67M | $9.25M | $10.68M | $8.20M | $5.73M | $6.83M | $7.16M |
| Selling and Marketing Expenses | $- | $- | $-786.00K | $-787.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $25.34M | $27.11M | $26.58M | $21.36M | $21.54M | $18.59M | $17.37M | $15.82M | $19.05M | $15.11M | $12.85M | $11.77M | $12.17M | $9.67M | $9.25M | $10.68M | $8.20M | $5.73M | $6.83M | $7.16M |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $-500.00K | $- | $- | $- | $-500.00K | $- | $- | $500.00K | $- | $- | $- | $- |
| Operating Expenses | $62.69M | $69.42M | $71.37M | $65.12M | $63.28M | $65.43M | $68.76M | $62.19M | $68.58M | $58.49M | $54.21M | $42.56M | $43.83M | $49.65M | $34.05M | $38.72M | $59.24M | $27.39M | $23.56M | $24.12M |
| Cost and Expenses | $62.69M | $69.42M | $73.71M | $67.38M | $63.28M | $65.43M | $68.76M | $62.19M | $68.58M | $58.49M | $54.21M | $42.56M | $43.83M | $49.65M | $34.05M | $38.72M | $59.24M | $27.39M | $23.56M | $24.12M |
| Interest Income | $2.84M | $3.18M | $4.54M | $5.79M | $4.09M | $4.00M | $3.52M | $4.33M | $1.25M | $1.35M | $669.00K | $623.00K | $849.00K | $806.00K | $501.00K | $272.00K | $237.00K | $518.00K | $429.00K | $967.00K |
| Interest Expense | $473.00K | $471.00K | $471.00K | $471.00K | $470.00K | $469.00K | $468.00K | $468.00K | $467.00K | $621.00K | $861.00K | $1.04M | $1.26M | $1.28M | $978.00K | $1.73M | $1.92M | $2.21M | $1.91M | $1.51M |
| Depreciation and Amortization | $2.36M | $2.39M | $2.34M | $2.25M | $2.37M | $1.76M | $1.72M | $1.67M | $1.78M | $1.64M | $1.57M | $1.30M | $3.19M | $800.00K | $700.00K | $674.00K | $630.00K | $273.00K | $124.00K | $118.00K |
| EBITDA | $-57.49M | $-63.86M | $-66.84M | $-59.33M | $-56.82M | $-59.67M | $-63.51M | $-56.19M | $-64.98M | $-55.66M | $-52.37M | $-41.22M | $-41.10M | $-48.78M | $-32.84M | $-37.78M | $-58.65M | $-26.81M | $-23.13M | $-22.97M |
| EBITDA Ratio | - | - | - | - | -551.05% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-62.69M | $-69.42M | $-73.71M | $-67.38M | $-63.28M | $-65.43M | $-68.76M | $-62.19M | $-69.08M | $-58.49M | $-54.21M | $-42.56M | $-44.33M | $-49.65M | $-34.05M | $-39.22M | $-59.24M | $-27.39M | $-23.56M | $-24.12M |
| Operating Income Ratio | - | - | - | - | -613.64% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $2.37M | $2.71M | $4.07M | $5.32M | $3.62M | $3.53M | $3.06M | $3.86M | $2.36M | $732.00K | $-192.00K | $-418.00K | $85.00K | $-472.00K | $-477.00K | $-957.00K | $-1.68M | $-1.69M | $-1.48M | $-544.00K |
| Income Before Tax | $-60.33M | $-66.72M | $-69.65M | $-62.05M | $-59.66M | $-61.90M | $-65.70M | $-58.34M | $-66.72M | $-57.76M | $-54.40M | $-42.98M | $-44.25M | $-50.12M | $-34.52M | $-40.18M | $-60.92M | $-29.08M | $-25.04M | $-24.66M |
| Income Before Tax Ratio | - | - | - | - | -578.55% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $- | $- | $- | $1 | $1.63M | $-1.76M | $3.52M | $-3.39M | $-2.36M | $-732.00K | $192.00K | $418.00K | $1.26M | $806.00K | $251.00K | $2.23M | $237.00K | $518.00K | $1.79M | $1.57M |
| Net Income | $-60.33M | $-66.72M | $-69.65M | $-62.05M | $-59.66M | $-61.90M | $-65.70M | $-54.94M | $-64.36M | $-57.02M | $-54.59M | $-43.40M | $-44.25M | $-50.12M | $-34.52M | $-40.18M | $-60.92M | $-29.08M | $-25.04M | $-24.66M |
| Net Income Ratio | - | - | - | - | -578.55% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-0.62 | $-0.71 | $-0.74 | $-0.66 | $-0.64 | $-0.75 | $-0.82 | $-0.69 | $-0.88 | $-0.86 | $-0.83 | $-0.67 | $-0.69 | $-0.79 | $-0.55 | $-0.65 | $-1.10 | $-0.53 | $-0.45 | $-0.45 |
| EPS Diluted | $-0.62 | $-0.71 | $-0.74 | $-0.66 | $-0.64 | $-0.75 | $-0.82 | $-0.69 | $-0.88 | $-0.86 | $-0.83 | $-0.67 | $-0.69 | $-0.79 | $-0.55 | $-0.65 | $-1.10 | $-0.53 | $-0.45 | $-0.45 |
| Weighted Average Shares Outstanding | 97.53M | 94.16M | 93.75M | 93.55M | 93.34M | 82.64M | 80.47M | 79.45M | 72.89M | 66.22M | 65.48M | 64.51M | 64.47M | 63.83M | 63.06M | 61.57M | 55.19M | 55.19M | 55.16M | 54.88M |
| Weighted Average Shares Outstanding Diluted | 97.53M | 94.16M | 93.75M | 93.55M | 93.34M | 82.64M | 80.47M | 79.45M | 72.89M | 66.22M | 65.48M | 64.51M | 64.47M | 63.83M | 63.06M | 61.57M | 55.19M | 55.19M | 55.16M | 54.88M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $163.63M | $55.90M | $140.52M | $232.69M | $297.10M |
| Short Term Investments | $208.70M | $317.27M | $215.88M | $156.05M | $185.62M |
| Cash and Short Term Investments | $372.34M | $373.18M | $356.39M | $388.74M | $482.72M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $5.85M | $5.05M | $7.67M | $6.64M | $9.25M |
| Total Current Assets | $378.18M | $378.22M | $364.06M | $392.06M | $487.35M |
| Property Plant Equipment Net | $83.32M | $87.59M | $77.64M | $72.35M | $70.64M |
| Goodwill | $39.15M | $39.15M | $39.15M | $30.82M | $30.82M |
| Intangible Assets | $25.15M | $25.15M | $25.72M | $- | $- |
| Goodwill and Intangible Assets | $64.30M | $64.30M | $64.88M | $30.82M | $30.82M |
| Long Term Investments | $- | $34.32M | $43.28M | $1.34M | $1.57M |
| Tax Assets | $- | $- | $- | $-1.34M | $-1.57M |
| Other Non-Current Assets | $1.89M | $1.91M | $1.95M | $1.80M | $2.02M |
| Total Non-Current Assets | $149.52M | $188.12M | $187.75M | $104.96M | $103.48M |
| Other Assets | $- | $- | $- | $0 | $0 |
| Total Assets | $527.70M | $566.34M | $551.81M | $497.02M | $590.82M |
| Account Payables | $- | $- | $- | $- | $- |
| Short Term Debt | $2.86M | $2.72M | $5.02M | $5.10M | $9.41M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $-36.66M | $-482 | $590.00K |
| Other Current Liabilities | $37.83M | $45.79M | $34.15M | $17.06M | $23.20M |
| Total Current Liabilities | $40.68M | $48.51M | $39.17M | $22.17M | $32.62M |
| Long Term Debt | $22.64M | $22.33M | $40.71M | $40.10M | $74.04M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.14M | $2.94M | $-17.76M | $-19.97M | $-19.35M |
| Total Non-Current Liabilities | $23.78M | $25.26M | $22.95M | $20.13M | $54.69M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $64.47M | $73.77M | $62.12M | $42.30M | $87.31M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.06M | $903.00K | $791.00K | $645.00K | $610.00K |
| Retained Earnings | $-1.22B | $-959.37M | $-713.77M | $-491.91M | $-322.84M |
| Accumulated Other Comprehensive Income Loss | $66.00K | $319.00K | $-357.00K | $-161.00K | $-42.00K |
| Other Total Stockholders Equity | $1.68B | $1.45B | $1.20B | $946.15M | $825.79M |
| Total Stockholders Equity | $463.23M | $492.57M | $489.69M | $454.72M | $503.52M |
| Total Equity | $463.23M | $492.57M | $489.69M | $454.72M | $503.52M |
| Total Liabilities and Stockholders Equity | $527.70M | $566.34M | $551.81M | $497.02M | $590.82M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $527.70M | $566.34M | $551.81M | $497.02M | $590.82M |
| Total Investments | $208.70M | $351.59M | $259.15M | $156.05M | $185.62M |
| Total Debt | $25.50M | $25.04M | $22.87M | $22.60M | $61.70M |
| Net Debt | $-138.14M | $-30.86M | $-117.65M | $-210.09M | $-235.40M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $163.63M | $65.60M | $38.61M | $35.28M | $55.90M | $225.66M | $45.08M | $64.58M | $140.52M | $196.67M | $187.55M | $130.55M | $232.69M | $245.64M | $264.61M | $252.54M | $297.10M | $82.23M | $163.20M | $190.52M |
| Short Term Investments | $208.70M | $170.06M | $240.22M | $295.04M | $317.27M | $211.51M | $261.96M | $266.50M | $215.88M | $109.86M | $133.82M | $216.04M | $156.05M | $175.81M | $162.22M | $213.81M | $185.62M | $146.46M | $86.60M | $85.38M |
| Cash and Short Term Investments | $372.34M | $235.66M | $278.82M | $330.31M | $373.18M | $437.17M | $307.04M | $331.08M | $356.39M | $306.53M | $321.37M | $346.59M | $388.74M | $421.46M | $426.83M | $466.35M | $482.72M | $228.69M | $249.80M | $275.89M |
| Net Receivables | $- | $- | $8.10M | $8.60M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-900.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $5.85M | $- | $5.80M | $14.85M | $5.05M | $9.69M | $5.03M | $6.95M | $7.67M | $9.19M | $8.81M | $7.25M | $6.64M | $7.22M | $7.19M | $10.94M | $9.25M | $9.05M | $11.27M | $7.82M |
| Total Current Assets | $378.18M | $241.75M | $292.73M | $345.16M | $378.22M | $446.87M | $312.07M | $338.03M | $364.06M | $311.13M | $325.77M | $353.85M | $392.06M | $425.07M | $430.43M | $471.82M | $487.35M | $233.21M | $255.44M | $279.81M |
| Property Plant Equipment Net | $83.32M | $85.77M | $87.54M | $88.08M | $87.59M | $85.68M | $82.92M | $81.09M | $77.64M | $73.51M | $73.47M | $73.69M | $72.35M | $72.57M | $72.12M | $71.93M | $70.64M | $69.44M | $64.83M | $60.15M |
| Goodwill | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M |
| Intangible Assets | $25.15M | $25.15M | $25.15M | $25.15M | $25.15M | $25.15M | $25.72M | $25.72M | $25.72M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $64.30M | $64.30M | $64.30M | $64.30M | $64.30M | $64.30M | $64.88M | $64.88M | $64.88M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M | $30.82M |
| Long Term Investments | $- | $- | $1.36M | $1.36M | $34.32M | $1.37M | $1.36M | $28.96M | $43.28M | $1.35M | $1.34M | $1.34M | $1.34M | $1.33M | $1.33M | $1.46M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $-1 | $- | $533.00K | $-1.37M | $-1.36M | $- | $- | $-1.35M | $-1.34M | $-1.34M | $-1.34M | $-1.33M | $-1.33M | $-1.46M | $- | $- | $- | $- |
| Other Non-Current Assets | $1.89M | $1.86M | $481.00K | $533.00K | $1.37M | $1.91M | $1.90M | $1.80M | $1.95M | $1.81M | $1.80M | $1.80M | $1.80M | $1.79M | $1.79M | $1.92M | $2.02M | $2.02M | $1.98M | $1.98M |
| Total Non-Current Assets | $149.52M | $151.93M | $153.69M | $154.28M | $188.12M | $151.90M | $149.71M | $176.72M | $187.75M | $106.13M | $106.08M | $106.30M | $104.96M | $105.17M | $104.73M | $104.66M | $103.48M | $102.28M | $97.63M | $92.95M |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $0 | $2.00K | $0 | $- | $- | $- | $0 | $- | $- | $- |
| Total Assets | $527.70M | $393.69M | $446.41M | $499.44M | $566.34M | $598.76M | $461.78M | $514.76M | $551.81M | $417.26M | $431.85M | $460.15M | $497.02M | $530.24M | $535.15M | $576.48M | $590.82M | $335.50M | $353.06M | $372.75M |
| Account Payables | $- | $- | $- | $2.75M | $- | $1.85K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Short Term Debt | $2.86M | $2.85M | $5.72M | $2.87M | $5.43M | $5.70M | $5.99M | $5.19M | $2.51M | $4.72M | $4.90M | $5.08M | $2.55M | $4.96M | $10.02M | $9.66M | $7.14M | $9.48M | $4.88M | $4.59M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $-2.75M | $-1.77K | $-1.85K | $-1.11K | $-1.67K | $-37.43M | $-1.88K | $-21.84M | $-965 | $-482 | $-651 | $-669 | $597.00K | $590.00K | $583.00K | $576.00K | $569.00K |
| Other Current Liabilities | $37.83M | $37.13M | $31.87M | $27.33M | $43.07M | $27.77M | $28.36M | $26.01M | $36.66M | $25.46M | $19.39M | $17.49M | $19.61M | $19.53M | $15.43M | $30.83M | $24.88M | $22.47M | $15.80M | $16.52M |
| Total Current Liabilities | $40.68M | $39.98M | $37.59M | $32.96M | $48.51M | $33.48M | $34.35M | $31.21M | $39.17M | $30.18M | $24.29M | $22.57M | $22.17M | $24.49M | $25.44M | $40.49M | $32.62M | $31.95M | $20.68M | $21.11M |
| Long Term Debt | $22.64M | $22.80M | $22.94M | $23.08M | $44.65M | $44.66M | $44.79M | $45.60M | $20.36M | $39.47M | $39.63M | $39.79M | $20.05M | $40.00M | $40.33M | $55.87M | $54.55M | $81.22M | $85.44M | $65.56M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.14M | $1.14M | $1.25M | $1.91M | $-19.39M | $-20.46M | $-20.32M | $-20.93M | $2.60M | $-19.70M | $-19.77M | $-19.83M | $80.00K | $-19.91M | $-20.06M | $122.00K | $136.00K | $-19.52M | $-19.58M | $23.00K |
| Total Non-Current Liabilities | $23.78M | $23.94M | $24.18M | $24.98M | $25.26M | $24.20M | $24.46M | $24.68M | $22.95M | $19.77M | $19.87M | $19.96M | $20.13M | $20.09M | $20.27M | $55.99M | $54.69M | $61.70M | $65.86M | $65.59M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $64.47M | $63.92M | $61.78M | $57.94M | $73.77M | $57.68M | $58.81M | $55.88M | $62.12M | $49.95M | $44.16M | $42.53M | $42.30M | $44.58M | $45.72M | $96.48M | $87.31M | $93.66M | $86.54M | $86.70M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.06M | $911.00K | $910.00K | $906.00K | $903.00K | $901.00K | $805.00K | $804.00K | $791.00K | $678.00K | $658.00K | $645.00K | $645.00K | $644.00K | $634.00K | $619.00K | $610.00K | $552.00K | $551.00K | $551.00K |
| Retained Earnings | $-1.22B | $-1.16B | $-1.09B | $-1.02B | $-959.37M | $-899.71M | $-837.81M | $-772.11M | $-713.77M | $-647.05M | $-589.30M | $-534.89M | $-491.91M | $-447.67M | $-397.55M | $-363.02M | $-322.84M | $-261.93M | $-232.85M | $-207.81M |
| Accumulated Other Comprehensive Income Loss | $66.00K | $213.00K | $-218.00K | $-135.00K | $319.00K | $-508.00K | $-722.00K | $-90.00K | $-357.00K | $-596.00K | $-765.00K | $-629.00K | $-161.00K | $-97.00K | $-81.00K | $-75.00K | $-42.00K | $69.00K | $229.00K | $-75.00K |
| Other Total Stockholders Equity | $1.68B | $1.49B | $1.48B | $1.46B | $1.45B | $1.44B | $1.24B | $1.23B | $1.20B | $1.01B | $977.10M | $952.50M | $946.15M | $932.78M | $886.43M | $842.48M | $825.79M | $503.15M | $498.59M | $493.38M |
| Total Stockholders Equity | $463.23M | $329.77M | $384.63M | $441.50M | $492.57M | $541.09M | $402.97M | $458.88M | $489.69M | $367.31M | $387.70M | $417.62M | $454.72M | $485.66M | $489.44M | $480.00M | $503.52M | $241.84M | $266.52M | $286.05M |
| Total Equity | $463.23M | $329.77M | $384.63M | $441.50M | $492.57M | $541.09M | $402.97M | $458.88M | $489.69M | $367.31M | $387.70M | $417.62M | $454.72M | $485.66M | $489.44M | $480.00M | $503.52M | $241.84M | $266.52M | $286.05M |
| Total Liabilities and Stockholders Equity | $527.70M | $393.69M | $446.41M | $499.44M | $566.34M | $598.76M | $461.78M | $514.76M | $551.81M | $417.26M | $431.85M | $460.15M | $497.02M | $530.24M | $535.15M | $576.48M | $590.82M | $335.50M | $353.06M | $372.75M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $527.70M | $393.69M | $446.41M | $499.44M | $566.34M | $598.76M | $461.78M | $514.76M | $551.81M | $417.26M | $431.85M | $460.15M | $497.02M | $530.24M | $535.15M | $576.48M | $590.82M | $335.50M | $353.06M | $372.75M |
| Total Investments | $208.70M | $170.06M | $241.58M | $296.40M | $34.32M | $211.51M | $261.96M | $28.96M | $259.15M | $109.86M | $133.82M | $216.04M | $156.05M | $175.81M | $162.22M | $213.81M | $185.62M | $146.46M | $86.60M | $85.38M |
| Total Debt | $25.50M | $25.64M | $25.80M | $25.95M | $25.04M | $25.18M | $25.39M | $25.40M | $22.87M | $22.09M | $22.27M | $22.43M | $22.60M | $22.48M | $27.73M | $63.20M | $61.70M | $68.80M | $68.27M | $67.86M |
| Net Debt | $-138.14M | $-39.96M | $-12.81M | $-9.33M | $-30.86M | $-200.47M | $-19.69M | $-39.18M | $-117.65M | $-174.58M | $-165.28M | $-108.12M | $-210.09M | $-223.16M | $-236.88M | $-189.34M | $-235.40M | $-13.42M | $-94.93M | $-122.66M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-258.75M | $-245.59M | $-221.86M | $-169.07M | $-139.70M |
| Depreciation and Amortization | $9.38M | $7.10M | $6.27M | $5.37M | $1.15M |
| Deferred Income Tax | $- | $- | $- | $3.15M | $999.00K |
| Stock Based Compensation | $43.92M | $39.41M | $31.01M | $29.24M | $18.57M |
| Change in Working Capital | $1.92M | $13.46M | $6.08M | $-3.39M | $15.03M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $9.67M | $-4.83M | $11.02M |
| Other Working Capital | $1.92M | $13.46M | $-3.60M | $1.44M | $4.01M |
| Other Non Cash Items | $-6.19M | $-9.28M | $370.00K | $13.53M | $29.32M |
| Net Cash Provided by Operating Activities | $-209.72M | $-194.92M | $-178.14M | $-121.16M | $-74.64M |
| Investments in Property Plant and Equipment | $- | $-16.47M | $-8.62M | $-7.71M | $-29.06M |
| Acquisitions Net | $- | $- | $42.73M | $95.00K | $8.45M |
| Purchases of Investments | $- | $-390.92M | $-376.33M | $-245.88M | $-209.34M |
| Sales Maturities of Investments | $- | $309.33M | $272.89M | $272.44M | $141.81M |
| Other Investing Activities | $131.71M | $- | $-103.69K | $-95.00K | $-8.45M |
| Net Cash Used for Investing Activities | $131.71M | $-98.07M | $-69.33M | $18.85M | $-96.59M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $185.74M | $208.39M | $155.34M | $37.68M | $281.35M |
| Common Stock Repurchased | $- | $- | $-47.00K | $- | $-72.00K |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $185.74M | $7.00K | $- | $- | $1.71M |
| Net Cash Used Provided by Financing Activities | $185.74M | $208.40M | $155.29M | $37.68K | $282.99M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $107.72M | $-84.58M | $-92.18M | $-64.63M | $111.76M |
| Cash at End of Period | $165.00M | $57.28M | $141.86M | $234.04M | $298.67M |
| Cash at Beginning of Period | $57.28M | $141.86M | $234.04M | $298.67M | $186.91M |
| Operating Cash Flow | $-209.72M | $-194.92M | $-178.14M | $-121.16M | $-74.64M |
| Capital Expenditure | $- | $-16.47M | $-8.62M | $-7.71M | $-29.06M |
| Free Cash Flow | $-209.72M | $-211.39M | $-186.76M | $-128.88M | $-103.70M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-60.33M | $-66.72M | $-69.65M | $-62.05M | $-59.66M | $-61.90M | $-65.70M | $-58.34M | $-66.72M | $-57.76M | $-54.40M | $-42.98M | $-44.25M | $-50.12M | $-34.52M | $-40.18M | $-60.92M | $-29.08M | $-25.04M | $-24.66M |
| Depreciation and Amortization | $2.36M | $2.42M | $2.34M | $2.25M | $1.94M | $1.76M | $1.73M | $1.67M | $3.38M | $1.08M | $496.00K | $1.30M | $3.19M | $808.00K | $706.00K | $674.00K | $630.00K | $273.00K | $124.00K | $118.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-12.47M | $12.47M | $- | $- | $- | $- | $- | $- | $1.06M | $743.00K | $726.00K | $620.00K | $631.00K | $243.00K | $125.00K | $- |
| Stock Based Compensation | $11.09M | $11.25M | $11.33M | $10.25M | $9.93M | $10.32M | $10.24M | $8.91M | $9.69M | $7.68M | $7.37M | $6.27M | $7.04M | $6.99M | $7.31M | $7.90M | $6.07M | $4.05M | $4.49M | $3.96M |
| Change in Working Capital | $-717.00K | $248.00K | $4.33M | $-4.58M | $21.53M | $-5.94M | $5.34M | $-7.47M | $170.00K | $4.45M | $5.89M | $-4.43M | $-3.18M | $6.54M | $-12.86M | $6.11M | $13.24M | $6.59M | $-2.30M | $-2.50M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $-2.41M | $17.90M | $- | $- | $-7.75M | $7.13M | $- | $2.55M | $-491.00K | $-4.83M | $- | $- | $7.05M | $11.02M | $- | $- | $-1.93M |
| Other Working Capital | $-717.00K | $248.00K | $4.33M | $-4.58M | $3.63M | $-5.94M | $5.34M | $7.75M | $-6.96M | $4.45M | $3.34M | $-3.94M | $1.65M | $6.08M | $-14.11M | $-934.00K | $2.23M | $6.59M | $-2.30M | $-572.00K |
| Other Non Cash Items | $653.00K | $699.00K | $13.80M | $12.01M | $9.39M | $-13.85M | $-2.49M | $-2.34M | $-2.54M | $690.00K | $1.61M | $617.00K | $5.20M | $7.62M | $116.00K | $589.00K | $27.23M | $669.00K | $572.00K | $844.00K |
| Net Cash Provided by Operating Activities | $-46.94M | $-52.10M | $-53.85M | $-56.88M | $-29.34M | $-57.15M | $-50.87M | $-57.56M | $-56.02M | $-43.86M | $-39.04M | $-39.22M | $-30.94M | $-27.41M | $-38.53M | $-24.28M | $-13.11M | $-17.25M | $-22.03M | $-22.25M |
| Investments in Property Plant and Equipment | $-309.00K | $-1.59M | $-1.93M | $-2.04M | $-4.65M | $-4.66M | $-4.15M | $-3.02M | $-3.26M | $-503.00K | $-2.90M | $-1.96M | $-2.04M | $-3.84M | $-1.51M | $-328.00K | $-14.92M | $-3.92M | $-4.39M | $-5.83M |
| Acquisitions Net | $- | $- | $- | $- | $81.23K | $-52.91K | $-35.33K | $7.00K | $42.73M | $-23.97K | $- | $- | $95.00K | $423.00K | $325.00K | $- | $-646.00K | $278.00K | $280.00K | $88.00K |
| Purchases of Investments | $-124.05M | $-19.32M | $-38.57M | $-63.95M | $-208.50M | $-13.49M | $-72.90M | $-96.03M | $-198.87M | $-34.44M | $-143.02M | $-143.02M | $-19.39M | $-67.91M | $-54.76M | $-103.81M | $-77.24M | $-75.67M | $-32.95M | $-23.48M |
| Sales Maturities of Investments | $86.48M | $99.83M | $96.13M | $101.02M | $72.34M | $66.40M | $108.25M | $62.34M | $50.82M | $58.41M | $81.69M | $81.98M | $38.30M | $53.56M | $105.61M | $74.97M | $37.70M | $15.40M | $31.91M | $56.80M |
| Other Investing Activities | $- | $- | $- | $37.07K | $-81.23K | $52.91K | $35.33K | $-7.00K | $-148.31K | $23.97K | $143.02M | $-61.04K | $-95.00K | $-423.00K | $-325.00K | $-28.85K | $646.00K | $-278.00K | $-280.00K | $-88.00K |
| Net Cash Used for Investing Activities | $-37.87M | $78.92M | $55.62M | $35.03M | $-140.81M | $48.25M | $31.21M | $-36.72M | $-108.58M | $23.46M | $78.79M | $-62.99M | $16.86M | $-18.19M | $49.35M | $-29.17M | $-54.46M | $-64.19M | $-5.43M | $27.50M |
| Debt Repayment | $- | $- | $29.00K | $27.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $182.85M | $176.00K | $1.53M | $1.18M | $391.00K | $189.49M | $182.00K | $18.34M | $107.86M | $29.53M | $17.25M | $76.00K | $-10.19M | $26.64M | $1.11M | $8.79M | $279.89M | $587.00K | $825.00K | $53.00K |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $-47.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-72.00K |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $176.00K | $- | $- | $- | $- | $- | $7.00K | $631.00K | $- | $- | $- | $1.14M | $- | $- | $- | $2.55M | $-75.00K | $-674.00K | $-98.00K |
| Net Cash Used Provided by Financing Activities | $182.85M | $176.00K | $1.56M | $1.21M | $391.00K | $189.49M | $182.00K | $18.34M | $108.44M | $29.53M | $17.25M | $76.00K | $1.14K | $26.64K | $1.11K | $8.79K | $282.44M | $512.00K | $151.00K | $-117.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $166.75M | $-166.75M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $98.04M | $26.99M | $3.33M | $-20.63M | $-169.75M | $180.59M | $-19.48M | $-75.94M | $-56.17M | $9.13M | $57.00M | $-102.14M | $-12.94M | $-18.96M | $11.94M | $-44.66M | $214.87M | $-80.93M | $-27.32M | $5.14M |
| Cash at End of Period | $165.00M | $66.96M | $38.61M | $35.28M | $57.28M | $227.03M | $46.44M | $65.92M | $141.86M | $198.02M | $188.89M | $131.90M | $234.04M | $246.98M | $265.94M | $254.00M | $298.67M | $83.79M | $164.73M | $192.04M |
| Cash at Beginning of Period | $66.96M | $39.97M | $35.28M | $55.90M | $227.03M | $46.44M | $65.92M | $141.86M | $198.02M | $188.89M | $131.90M | $234.04M | $246.98M | $265.94M | $254.00M | $298.67M | $83.79M | $164.73M | $192.04M | $186.91M |
| Operating Cash Flow | $-46.94M | $-52.10M | $-53.85M | $-56.88M | $-29.34M | $-57.15M | $-50.87M | $-57.56M | $-56.02M | $-43.86M | $-39.04M | $-39.22M | $-30.94M | $-27.41M | $-38.53M | $-24.28M | $-13.11M | $-17.25M | $-22.03M | $-22.25M |
| Capital Expenditure | $-309.00K | $-1.59M | $-1.93M | $-2.04M | $-4.65M | $-4.66M | $-4.15M | $-3.02M | $-3.26M | $-503.00K | $-2.90M | $-1.96M | $-2.04M | $-3.84M | $-1.51M | $-328.00K | $-14.92M | $-3.92M | $-4.39M | $-5.83M |
| Free Cash Flow | $-47.25M | $-53.69M | $-55.78M | $-58.92M | $-33.99M | $-61.80M | $-55.02M | $-60.58M | $-59.28M | $-44.36M | $-41.94M | $-41.18M | $-32.98M | $-31.25M | $-40.03M | $-24.61M | $-28.03M | $-21.18M | $-26.42M | $-28.07M |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
$7.63
Stock Price
$813.59M
Market Cap
299
Employees
Cranbury, NJ
Location
Revenue (FY 2024)
$-
0.0% YoY
Net Income (FY 2024)
$-258.75M
-5.4% YoY
EPS (FY 2024)
$-2.73
6.5% YoY
Free Cash Flow (FY 2024)
$-209.72M
0.8% YoY
Profitability
Gross Margin
0.0%
Net Margin
0.0%
ROE
-55.9%
ROA
-49.0%
Valuation
P/E Ratio
-4.61
P/S Ratio
0.00
EV/EBITDA
-3.86
Market Cap
$813.59M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-209.72M
-7.6% YoY
Free Cash Flow
$-209.72M
0.8% YoY
Balance Sheet Summary
Total Assets
$527.70M
-6.8% YoY
Total Debt
$25.50M
1.8% YoY
Shareholder Equity
$463.23M
-16.7% YoY
Dividend Overview
No Dividend Data
Rocket Pharmaceuticals, Inc. doesn't currently pay dividends.
Rocket Pharmaceuticals Dividends
Explore Rocket Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Rocket Pharmaceuticals News
Read the latest news about Rocket Pharmaceuticals, including recent articles, headlines, and updates.
Rocket Pharma Out Of Orbit, But Ready For Relaunch
Rocket Pharmaceuticals' gene therapies offer long-term effects for cardiovascular and hematology diseases, addressing severe unmet needs like Danon Disease, which currently requires heart transplants. The near-term outlook driven by clinical milestones for RP-A601, RP-A501, and potential Kresladi approval, with the current share price at $5 offering significant value. Rocket has $372M in cash, funding operations through 1H 2026, but will likely need financing post-positive data readout or Kresladi approval for commercialization.
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that management will participate in the 24th Annual Needham Virtual Healthcare Conference taking place on April 8, 2025. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat at 8:45 a.m. ET on Tuesday, April 8. A webcast of the fire.
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and year ended December 31, 2024. “In 2024, we made strong progress in advancing our gene therapy pipeline, underscored by the New England Journal of Medicine publication of the Phase 1 study of.
Rocket Pharma Is A Buy At These Prices With Promising Data
Rocket Pharmaceuticals, Inc.'s RP-L201 for LAD-I faces FDA rejection but shows promising data; potential approval could unlock a $350M market. RP-L102 for Fanconi Anemia and RP-A501 for Danon Disease show strong clinical data, indicating significant market potential. Financially, Rocket Pharma has a limited cash runway of 2–4 quarters, dependent on FDA approvals and successful public offerings.
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, in San Francisco, California. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Monday, January 13, at 3:45 p.m. PT and host investor meetings throu.
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'
Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism about the experimental drugs in its pipeline. Jefferies also set a price target of $29, more than double its current value.
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today that it intends to offer and sell $150 million of shares of its common stock in an underwritten public offering. In addition, Rocket intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of shares of its common stock o.
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 7th Annual Evercore HealthCONx Conference in Miami, Florida. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 3, at 1:45 p.m. ET and host investor meetings throughout.
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, presented long-term safety and efficacy results from the Phase 1 RP-A501 study which showed that RP-A501 was generally well tolerated and all evaluable Danon disease patients demonstrated LAMP2 protein expression at 12 months (sustained up to 60 months) and reduction of le.
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting new data on the results of the RP-A501 Phase 1 trial to treat patients with Danon disease at the American Heart Association's 2024 Late-Breaking Science sessions being held from November 16-18, 2024 in Chicago, Illinois.
Rocket Pharmaceuticals price target raised to $51 from $50 at Scotiabank
Scotiabank raised the firm's price target on Rocket Pharmaceuticals to $51 from $50 and keeps an Outperform rating on the shares. The company provided "a slew of positive updates," which included an announcement of updated phase 1 data for RP-A501, the analyst tells investors. Rocket continues to have positive momentum with the potential to have multiple marketed products within the next 12 months, the firm adds.
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, November 12, at 5:00 p.m. PT. A webcast of the fireside chat will.
Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves
Enrollment completed for pivotal single-arm phase 2 study, using RP-A501 for the treatment of male patients with Danon disease. Promise for RP-A501 program lies with the potential to receive FDA Accelerated Approval for the treatment of male patients with Danon disease. The Danon disease treatment market is expected to reach $2.82 billion by 2030.
3 Biotech Names With Potential Catalysts By Year End
The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should continue to advance. Today, we look in more detail at three small/mid-cap biotech stocks with potential catalysts that should hit before the end of 2024.
FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment
Rocket Pharmaceuticals (RCKT) shares declined in intraday trading Friday after the biopharmaceutical firm announced that the Food and Drug Administration (FDA) wants more data about its gene therapy to treat a rare immune disorder in children before granting approval.
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a lentiviral (LV) vector-based gene therapy to treat severe leukocyte adhesion deficiency-I (LAD-I). The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter.
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has granted orphan medicinal product designation for RP-A601, the Company's adeno-associated.
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced longer-term data updates from its lentiviral (LV) vector hematology portfolio presented at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Data updates demonstrate the continued safety and efficacy of the Phase 1/2 pivotal.
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024. “Rocket has had a strong start to 2024. This quarter has been marked by meaningful progress across all our clinical programs, most notably with the EMA's review of RP-L102 for Fa.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for RCKT.